Chen et
Our study provided additional data in the Chinese setting, complementing the previous evidence on once-weekly semaglutide versus sitagliptin of foreign populations, and provided insights to assist decision makers in choosing between the two drugs based on their value for money
Enter the Dual and Triple Agonists To break through this ceiling, scientists began combining hormone targets: Dual Agonists (GLP-1 + GIP): Tirzepatide (Mounjaro, Zepbound) was the first commercially approved dual agonist
Bekhbat M, Treadway M, Felger J
For twice-daily administration, administer in the AM and at bedtime
This frequency allows for sustained receptor activation over seven days, with peak plasma concentration occurring 1-3 days post-injection, then gradual decline until the next dose